Generated by Codex with GPT 5.6 Sol XHigh

Techmeme surfaced the July 22, 2026 development in its PRIMA bionic-eye item, led by the Financial Times report US start-up wins EU approval for sight-restoring bionic eye. Science Corporation’s commercial-launch announcement and the underlying clinical study provide the technical and medical context.

The important word in “bionic eye” is not eye but interface. PRIMA does not heal damaged photoreceptors or recreate ordinary sight. It inserts a new path between a camera and the surviving neural circuitry of the retina, giving some people with advanced age-related macular degeneration enough artificial central vision to read letters, numbers, and words.

That limited achievement is still a major one. Science Corporation says PRIMA has received a CE mark under the European Union’s Medical Device Regulation, authorizing commercial availability across 30 European countries. The company expects the first commercial implant in Germany and is activating clinical sites and pursuing reimbursement country by country. In the United States, the device has FDA Breakthrough Device and Humanitarian Use Device designations, but it has not yet received approval for sale.

Replacing a Missing Layer of the Retina

Geographic atrophy, an advanced form of dry age-related macular degeneration, destroys light-sensitive cells in the macula—the part of the retina responsible for detailed central vision. A person may retain peripheral sight yet lose the ability to read, recognize faces, or see what they are looking directly at. Existing treatments may try to slow progression in some patients, but they do not restore the central vision already lost.

PRIMA works around that damage. A surgeon places a wireless photovoltaic array measuring roughly 2 by 2 millimeters beneath the atrophied macula. Camera-equipped glasses capture a scene, and a portable processor can simplify or magnify the image. The glasses then project the processed pattern into the eye with near-infrared light. Photodiodes in the implant turn that light into electrical current, stimulating remaining retinal neurons that pass a signal through the optic nerve to the brain.

The design matters because the implant contains no battery and needs no cable crossing the wall of the eye. The external glasses supply both the visual pattern and the energy that activates the chip. Transparent lenses also allow the wearer to use natural peripheral vision at the same time as the prosthetic central image. Instead of replacing the whole visual system, PRIMA adds a small electronic island inside an area where photoreceptors have died.

The resulting perception is not natural vision. It is suited to high-contrast form and text, requires specialized glasses and rehabilitation, and can use digital zoom to enlarge small print. Current reporting describes it as monochrome rather than color vision, with too little visual richness for dependable face recognition. The achievement is therefore closer to restoring a functional reading channel than restoring an eye to normal.

A Meaningful Result With a Serious Surgical Cost

The evidence behind the approval comes from PRIMAvera, an open-label, prospective, single-group study funded in part by Science Corporation. Thirty-eight people with severe central vision loss received implants at 17 sites in five European countries. Thirty-two were available for the 12-month vision assessment.

Among those 32 participants, 26—81%—improved by at least 0.2 logMAR, the trial’s threshold for a clinically meaningful gain of roughly two lines on a standard eye chart. After statistical adjustment for the six people without 12-month measurements, the estimated response rate for all participants was 80%. The company’s announcement reports an average gain of 25.5 letters, or more than five chart lines, and says 84% of participants could read letters, numbers, and words with the system. Mean natural peripheral visual acuity remained equivalent to baseline.

Those numbers should not be detached from the safety results. The study recorded 26 serious events related to the procedure or to the procedure and device in 19 of the 38 participants. They included complications associated with retinal surgery, such as elevated eye pressure, retinal breaks, macular holes, bleeding, and retinal detachment. Twenty-one events occurred within two months of surgery, and 20 of those resolved within two months of onset. No serious event was attributed to the device alone, but half the small study population experienced at least one serious related event.

The trial also lacked a randomized control group, involved highly selected patients, and measured only 12-month primary outcomes. It does not yet establish how well the system will work across a broader population, how durable the benefit will be over many years, whether hardware and software support will remain available, or how consistently improved chart reading translates into everyday independence. Earlier retinal prostheses showed that regulatory approval alone does not guarantee long-term commercial viability or continued support for implanted users.

From Clinical Result to Supported Infrastructure

The CE mark turns PRIMA from an experimental result into a delivery problem. Successful use requires trained retinal surgeons, careful patient selection, rehabilitation, wearable hardware, software, maintenance, reimbursement, and a company capable of supporting an implant for years. Commercial availability across Europe therefore does not mean immediate access across Europe; the real rollout will proceed clinic by clinic and payer by payer.

That transition is what makes the story more important than another brain-computer-interface demonstration. PRIMA is a narrow, purpose-built neural interface reaching the market for a defined disease and a measurable function. It shows a plausible route for neurotechnology: start with a damaged biological pathway whose input and output can be identified, build an electronic bridge around the missing layer, and accept a constrained but valuable capability rather than promising general enhancement.

The balanced takeaway is neither that blindness has been cured nor that the improvement is merely symbolic. For some people who had lost central sight to geographic atrophy, a small implant and external glasses produced enough form vision to read again. European approval now tests whether that result can become a durable medical service without minimizing the surgery, training, support, and uncertainty that come with it.